Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure

September 15, 2003

(Philadelphia, PA) - The events that lead to cardiac hypertrophy, the enlargement of heart muscle cells, may be stopped by histone deacetylase (HDAC) inhibitors, a class of therapeutic agents currently under development as cancer drugs, according to researchers at the University of Pennsylvania School of Medicine. Cardiac hypertrophy is one of the leading causes of congestive heart failure, the most common diagnosis given for discharged hospital patients in the United States.

In the September issue of Journal of Clinical Investigation, the Penn researchers suggest novel genetic causes for - and new therapeutic agents against - cardiac hypertrophy and heart failure. Furthermore, the researchers demonstrate that anti-HDAC drugs can block the development of hypertrophy in animal models.

"In our studies, we determined that valproic acid, an HDAC inhibitor used to treat seizure disorders, is effective in preventing heart muscle cells from enlarging," said Jonathan A. Epstein, MD, Associate Professor in the division of Cardiovascular Medicine within Penn's Department of Medicine. "In recent years, drug companies have also begun developing more advanced HDAC inhibitors to treat cancer. These HDAC inhibitors may be among the first known medications to prevent cardiac hypertrophy."

Cardiac hypertrophy can be a healthy physiological response to events, such as aerobic exercise, where heart cells grow larger like any other well-conditioned muscle. Pathological hypertrophy, however, may result from genetic mutation or, most commonly, from the consequences of an unhealthy cardiovascular system.

"The exertion of pushing blood against high resistance in the setting of high blood pressure or overcompensation for heart muscle lost during a heart attack can cause heart muscle cells to enlarge," said Epstein. "While it might be helpful at first, hypertrophy can increase the stress placed on the heart and begin a downward spiral of events that ultimately leads to heart failure. Despite the fact that this is a common every-day problem for clinicians and patients, we have very few, if any, medications that are directed at halting the cellular events responsible for this deterioration. That's why our present studies are so encouraging."

Unlike most cells, cardiac muscle cells largely stop dividing after birth and only then grow larger through hypertrophy. The disease form of hypertrophy is associated with the re-activation of a genetic program that normally stops soon after birth. "Mature heart cells are naturally programmed to be anti-hypertophic, but mutation or the cumulative effects of cellular stress seems to restart a program of events that we've only seen in developing fetuses, " said Epstein. Epstein and his colleagues previously linked fetal cardiac development to a protein called Hop, which is thought to control heart cell growth. Hop is abundant in fetuses and newborns, but less so in adults, where it seems that the over-production of Hop overrides the cell's normal genetic programming. Hop does so by recruiting HDAC, which blocks a set of genes that normally protect the heart from hypertrophy. In effect, HDAC unlocks genes that have been kept hidden since birth.

"This genetic control of cell growth is why HDAC inhibitors also make for promising anti-cancer drugs," said Epstein. "Although we do not know for certain what this genetic program entails, it clearly results in severe cardiac hypertrophy and premature death in animal models." The elucidation of these chemical pathways and genetic programs will offer more new targets for the treatment of congestive heart failure, Epstein believes. The Penn researchers hope to continue to study HDAC inhibitors and their possible therapeutic roles in clinical trials to prevent hypertrophy in at-risk patients.
-end-
Contributing Penn researchers include Hyun Kook, John Lepore, Aaron D. Gitler, Min Min Lu, and Victor Ferrari from the Division of Cardiovascular Medicine and Rong Zhou from the Department of Radiology. Other contributing researchers include Wendy Wing-Man Yung and Joel Mackay from the University of Sydney and Peter Gruber from The Children's Hospital of Philadelphia.

University of Pennsylvania School of Medicine

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.